|
Middle Cerebral Artery Occlusion
|
0.310 |
Biomarker
|
disease |
CTD_human |
In this study, we found that Smox expression was increased in a rat middle cerebral artery occlusion (MCAO) model and in cultured primary neurons after oxygen-glucose deprivation and reoxygenation (OGD/R).
|
30576531 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that Smox expression was increased in a rat middle cerebral artery occlusion (MCAO) model and in cultured primary neurons after oxygen-glucose deprivation and reoxygenation (OGD/R).
|
30576531 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Middle Cerebral Artery Thrombosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Infarction, Middle Cerebral Artery
|
0.300 |
Biomarker
|
disease |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke.
|
16269634 |
2005 |
|
Cystic Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The virulence-related quorum-sensing (QS) regulon of LES431, an isolate that caused pneumonia in the non-CF parent of a CF patient, was considerably up-regulated in comparison to either isolate LES400, associated with a chronic CF infection, or strain PAO1.
|
15995206 |
2005 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that GaPPIX is indeed capable of inhibiting the growth of clinical <i>P. aeruginosa</i> strains under iron-deplete conditions, as those encountered by bacteria during infection, and that GaPPIX inhibition is reversed by iron.Using <i>P. aeruginosa</i> PAO1 as model organism, we show that GaPPIX enters cells through both the heme-uptake systems <i>has</i> and <i>phu</i>, primarily <i>via</i> the PhuR receptor which plays a crucial role in <i>P. aeruginosa</i> adaptation to the CF lung.
|
28184354 |
2017 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, the reference strain PAO1 and clonal pairs of CF clinical hypermutable and wild-type P. aeruginosa strains belonging to different genotypes were subjected to competition experiments in vitro and in a mouse model of chronic infection.
|
22294647 |
2012 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AM and DC were susceptible to cell death induced by the laboratory PA isolates PAO1, PAK and PA103, as well as a mucoid derivative of PAO1 and PA isolates derived from sputum of individuals with CF.
|
12409507 |
2002 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results demonstrate that a mucoid CF isolate of P. aeruginosa responds to biofilm-associated growth and [Ca2+] in a fashion similar to strain PAO1, but that strain-specific differences may allow this CF isolate to successfully colonize the pulmonary environment.
|
17975093 |
2007 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated this by performing both SWATH mass spectrometry and data-dependent SPS-MS3 of TMT-labeled peptides to profile the proteomes of two P. aeruginosa CF isolates, PASS2 and PASS3, and a laboratory reference strain, PAO1, grown under hypoxic stress (O<sub>2</sub> < 1%) in media that mimic the nutrient components of the CF lung.
|
28832155 |
2017 |
|
Cystic Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the secretome of an acute, transmissible CF P. aeruginosa (Australian epidemic strain 1-R; AES-1R) compared with laboratory-adapted PAO1.
|
23991618 |
2013 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Pseudomonas aeruginosa</i> is an opportunistic pathogen found ubiquitously in the environment and commonly associated with airway infection in patients with cystic fibrosis.<i>P. aeruginosa</i> strain PAO1 is one of the most commonly used laboratory-adapted research strains and is a standard laboratory-adapted strain in multiple laboratories and strain banks worldwide.
|
30530517 |
2019 |
|
Cystic Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PAO1 exoproducts also dampened F508del-CFTR rescue by VRT-325 or Vx-809 correctors in CF cells, whereas PAO1Δ<i>lasR</i> had no impact.Importantly, treatment of <i>P. aeruginosa</i> cultures with a quorum sensing inhibitor (HDMF) prevented the negative effect of <i>P. aeruginosa</i> exoproducts on wt-CFTR and preserved CFTR rescue by correctors in CF AEC.
|
29177135 |
2017 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These variations indicate significant differences between the metabolism and physiology of P. aeruginosa CF isolates and PAO1 that cannot be detected at the genome level alone.
|
26431321 |
2015 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report that glycerol metabolism promotes biofilm formation by both a chronic CF isolate (FRD1) and a wound isolate (PAO1) of P. aeruginosa.
|
27392247 |
2016 |
|
Cystic Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report, we show that mutations in the muc loci, (muc-2, muc-22, and muc-23, in the standard genetic P. aeruginosa strain PAO, as well as a mapped muc allele in an isolate from a cystic fibrosis patient) affect transcription of algD and algR.
|
2140147 |
1990 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While a reduction in cell growth was observed after 8 h of CORM application, either no effect or even a slight increase in cell densities and the amount of biofilm was observed after 24 h. This variation could be partly explained by differences in bacterial virulence traits: while CF isolates showed attenuated <i>in vivo</i> virulence and growth compared to strain PAO1, they formed much more biofilm, which could have potentially protected them from the CORM.
|
29472912 |
2018 |
|
Cystic Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A PAO1ΔoprD mutant was complemented with the oprD genes from five carbapenem-resistant CF strains exhibiting very low amounts of mutated OprD porins in their outer membrane despite wild-type levels of oprD transcripts.
|
25735764 |
2015 |
|
Cystic Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Infection with the P. aeruginosa strain PAO1 up-modulated the expression of 14 (27%) genes in IB3-1 cells and 15 (29%) genes in CF primary respiratory epithelia grown at an air-liquid interface, including chemokines (IL-8, growth-regulated Gro-α/β/γ proteins, and granulocyte chemotactic peptide-2 [GCP-2]), proinflammatory cytokines (IL-1α/β, IL-6, and TNF-α), and the intercellular adhesion molecule-1, nuclear factor kB1, toll like receptor 2, and human defensin B4 genes, confirming that bronchial epithelium is an important source of inflammatory mediators.
|
21659660 |
2011 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion mutations of efhP were generated in P. aeruginosa strain PAO1 and CF pulmonary isolate, strain FRD1.
|
24918783 |
2014 |
|
Cystic Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By exploiting this unstable phenotype, we isolated 34 spontaneous nonmucoid variants arising from the mucoid strain PDO300, a PAO1 derivative containing the <i>mucA22</i> allele commonly found in mucoid CF isolates.
|
29784885 |
2018 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we evaluate the volatile metabolites produced by P. aeruginosa (PAO1)-infected, RSV-infected, co-infected, or uninfected CF bronchial epithelial (CFBE) cells, in vitro.
|
29735804 |
2018 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the induction of apoptosis in response to Pseudomonas aeruginosa PAO1 in normal cells and several cystic fibrosis (CF) and corrected cell lines.
|
10970820 |
2000 |